奈拉替尼联合卡培他滨治疗HER2阳性晚期乳腺癌患者的临床研究OA北大核心CSTPCD
Clinical trial of naratinib combined with capecitabine in the treatment of advanced breast cancer patients with HER2 positive
目的 观察马来酸奈拉替尼片联合卡培他滨片治疗人表皮生长因子受体-2(HER2)阳性晚期乳腺癌患者的临床疗效及安全性.方法 将HER2阳性晚期乳腺癌患者随机分为对照组和试验组.对照组给予1 250 mg·m-2卡培他滨片,bid,口服给药,治疗2周后停药1周;试验组在对照组治疗的基础上,联合马来酸奈拉替尼片240 mg,qd,口服.2组患者均持续用药至疾病进展或患者无法耐受为止,每3周为1个疗程.比较2组患者的临床疗效、肿瘤标志物水平、生存情况,并…查看全部>>
Objective To observe the clinical efficacy and safety of naratinib maleate tablets combined with capecitabine tablets in the treatment of advanced breast cancer patients with human epidermal growth factor receptor 2(HER2)positive.Methods The advanced breast cancer patients with HER2 positive were randomly divided into control group and treatment group.The control group was given 1 250 mg·m-2 capecitabine tablets,bid,orally administered,and stopped for 1 week…查看全部>>
张团结;巩福玉;卢玉宁;丁亮;李想
阜阳市妇女儿童医院甲乳外科,安徽阜阳 236000阜阳市妇女儿童医院甲乳外科,安徽阜阳 236000阜阳市妇女儿童医院甲乳外科,安徽阜阳 236000阜阳市妇女儿童医院甲乳外科,安徽阜阳 236000阜阳市妇女儿童医院甲乳外科,安徽阜阳 236000
药学
马来酸奈拉替尼片卡培他滨片人表皮生长因子受体-2阳性晚期乳腺癌临床疗效安全性评价
naratinib maleate tabletcapecitabine tablethuman epidermal growth factor receptor 2 positiveadvanced breast cancerclinical efficacysafety evaluation
《中国临床药理学杂志》 2024 (17)
2474-2478,5
阜阳市科技技术局基金资助项目(FK202081119)
评论